𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Receptor specificity of the 5HT2 receptor antagonist, LY53857

✍ Scribed by Dr. Marlene L. Cohen; Walter Colbert; Laura A. Wittenauer


Publisher
John Wiley and Sons
Year
1985
Tongue
English
Weight
493 KB
Volume
5
Category
Article
ISSN
0272-4391

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Comparative 5-HT4 receptor antagonist ac
✍ Marlene L. Cohen; William Bloomquist; David Calligaro; Steven Swanson πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 148 KB

LY353433 is a selective, potent, and orally active 5-HT 4 receptor antagonist with a long duration of pharmacological activity following its oral administration to rats. After oral administration of LY353433 (100 mg/kg) to rats, peak plasma concentration of the parent material was approximately 25 n

Effects of serotonin receptor antagonist
✍ FranΓ§ois Jenck; Chris L. E. Broekkamp; Anton M. L. Delft πŸ“‚ Article πŸ“… 1989 πŸ› Springer 🌐 English βš– 895 KB

The effects of serotonin receptor antagonists with differential selectivity for the various classes of 5HT receptors (5HT1, 5HT2 and 5HT3) were tested for their effects on the response to aversive brain stimulation. Electrical stimulation was administered to the dorsal part of the periaqueductal gra

Neurochemical profile in vitro of irinda
✍ John Hyttel; Klaus BΓΈGesΓΈ; Hanne LΓΈVe LembΓΈL; Jens-JΓΈRgen Larsen; Eddi Meier πŸ“‚ Article πŸ“… 1988 πŸ› John Wiley and Sons 🌐 English βš– 866 KB

A new potential antihypertensive drug, irindalone (Lu 21 -098;( +)-(1 R,3S)-1-[2-[4-[3-(pf luoropheny1)-1 -indanyl]-1 -piperazinyl]ethyl]-2-imidazolidinone), has been characterized by a series of in vitro methods. lrindalone competitively inhibits peripheral and central serotonin;! (5-HT2) receptors